Tecan Revises 2024 Outlook Amid Market Challenges
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
- Latest
- Trending
Tecan reports lower H1 2024 sales, revises full-year outlook due to biopharma sector weakness and market challenges in China.
Bio-Techne shows resilience with strategic growth in diagnostics despite fiscal year challenges and market declines.
E3technology enhances Empore™ membranes for better proteome sample prep, crucial for low-cell proteomics, say experts at UD and CDS Analytical.
JPMorgan upgrades Bruker Corporation to Overweight, raising price target from $60 to $90, following strong Q4 performance and optimistic 2024 ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.